<DOC>
	<DOCNO>NCT01142063</DOCNO>
	<brief_summary>The purpose study demonstrate bioequivalence propose commercial neratinib tablet formulation ( 240 mg strength x 1 ) reference Phase 3 tablet formulation ( 40 mg tablet strength x 6 ) feed fasted condition healthy subject .</brief_summary>
	<brief_title>A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects</brief_title>
	<detailed_description>The study open label , randomize , 4 period , 4 treatment , 4 sequence ( Williams design ) , cross .</detailed_description>
	<criteria>An informed consent document sign date subject legally acceptable representative . Healthy male and/or female nonchildbearing potential subject age 18 55 year , inclusive ( healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG , clinical laboratory test ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Neratinib</keyword>
</DOC>